Bisoprolol Abrupt Discontinuation Effects (Class β-Blocker Withdrawal)
Abrupt cessation of long-term β-blocker therapy can cause a “rebound phenomenon” with increased adrenergic activity, leading to clinical deterioration in susceptible patients. [2] Rebound manifestations can occur during a window that extends from about 1 day to as long as 2 weeks after discontinuation. [4]
Expected Physiologic Changes After Sudden Cessation
β-blocker withdrawal can result in loss of β-receptor blockade with subsequent β-adrenergic hypersensitivity. [4] This mechanism is associated with rises in heart rate and blood pressure. [4] This mechanism is also associated with exacerbation of ischemic symptoms and higher risk of arrhythmias. [4]
Cardiovascular Clinical Effects That May Develop
Angina exacerbation can occur after abrupt β-blocker withdrawal in patients with coronary disease or prior antianginal need. [2] An increased risk for acute coronary events and sudden death has been described for abrupt β-blocker withdrawal, and guideline language highlights avoidance and tapering when feasible. [2] Bradycardia-related adverse effects may reverse after discontinuation, but the principal concern is the rebound adrenergic state. [2]
Timing of Effects Relevant to a 2-Week Stop
Rebound effects may appear within 1 day after stopping and may persist or be detectable up to 2 weeks after discontinuation. [4] For a 2-week abrupt stop, rebound-related symptoms can still fall within the expected risk window described in the literature. [4]
Evidence From Human Studies
Abrupt withdrawal of atenolol in hospitalized patients with severe stable angina has been studied, demonstrating clinically important withdrawal-related deterioration in that setting. [5] A classic report of propranolol withdrawal described a rebound phenomenon with exacerbation of coronary events after abrupt cessation of therapy. [3]
Guideline-Based Risk-Mitigation Implications
Abrupt withdrawal of β-blockers is recommended to be avoided in patients with heart failure because it can lead to clinical deterioration. [2] In stable ischemic heart disease, abrupt β-blocker withdrawal should be avoided because β-receptor density and sensitivity can increase, resulting in rebound phenomenon associated with increased risk of AMI and sudden death. [2] When withdrawal is necessary in stable ischemic heart disease, tapering over a 1–3 week period is recommended. [2]
Symptom Triggers and Urgency Indicators (Clinical Presentation Patterns)
Concerning rebound ischemic presentations include new or worsening angina symptoms after stopping. [2] Concerning rebound cardiovascular presentations include tachycardia, blood pressure rise, and new arrhythmic symptoms (for example, palpitations with dizziness or syncope). [4] Acute coronary syndrome presentations after withdrawal include chest pain consistent with myocardial ischemia and symptoms concerning for sudden clinical deterioration. [2]
Practical Clinical Management Direction
A medication change that includes stopping a chronic β-blocker should be planned with tapering rather than abrupt discontinuation in patients with ischemic heart disease or heart failure, based on guideline recommendations. [2] If urgent cardiovascular symptoms occur after withdrawal, immediate clinical evaluation is indicated because severe events have been described in the rebound setting. [2]